Promising data for advanced melanoma patients
9 October 2019
Melanoma Institute Australia (MIA) has presented promising data regarding progression-free survival rates for advanced melanoma patients at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona.
The overall survival rate at 3 years on the combination treatment was 49%, on single therapy was 42%, and a final cohort – those patients who would usually have been excluded from clinical trials because of the severity of their brain metastases – was 19%, which is a significant increase in life expectancy for these patients.
Five-year survival rates from the longest-running phase III trial of combination immunotherapy in melanoma patients were also presented at ESMO. The overall survival for those patients on combination ipilimumab and nivolumab was 52%, with 36% of patients progression-free.
Also on display at ESMO were four posters from our researchers. Post-doctoral researcher Dr. Ines da Silva presented our findings on the overall survival of melanoma patients based on the pattern of their metastases, and was awarded the best poster presentation at ESMO. She found that patients with brain metastases and liver metastases lived for shorter periods than patients without melanoma in these sites. She also found that different metastatic sites were asociated with different patterns of further metastasis, indicating that patterns of metastasis may be another helpful factor in determining prognosis.
Medical oncology Fellow Dr. Adriana Hepner presented data on the efficacy and safety of immunotherapy treatment after a patient has become resistant to combination immunotherapy. She found that giving patients immunotherapy again after they have already become resistant benefited a small subset of patients, although patients may have a recurrence of previous toxicities. This poster highlighted the need for further research into new and different treatments for these patients.
Medical oncologist and MIA PhD student Dr. Kazi Nahar's, presented her work on the characteristics of one of the major immune-related toxicities caused by immunotherapy treatment – colitis, or inflammation of the inner lining of the colon. She found that combination immunotherapy - while being highly effective for many melanoma patients - was more likely to cause earlier onset and more severe colitis in melanoma patients that also seems to be more resistant to steroid treatment.
Finally, PhD student Hansol Lee presented a poster that discussed the role of a type of immune cell called macrophages, on response to combination immunotherapy. He found that patients who responded to treatment had more macrophages within their tumour before they began treatment, and a higher amount of a particular subset of macrophages is associated with a significantly better overall response and progression-free survival rate.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina this October, to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Melanoma research saved Bert's life at 101 and now he wants to give back.
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.